Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): A retrospective study of 23 cases (2002-2007)

Veterinary and Comparative Oncology

Volumn 7, Issue 4, 2009, Pages 213-221

  Borrego, J F ^a   Cartagena, J C ^b   Engel, J ^c  

^a Nexo group   (Spain)

^b Old Golfhouse Veterinary Group   (United Kingdom)

^c Broadway Veterinary Hospital   (United Kingdom)

Author keywords

Chemotherapy; COX 2 inhibitor; Feline; Mammary tumours; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL; ARTICLE; CAT; CAT DISEASE; CLASSIFICATION; EXPERIMENTAL NEOPLASM; FEMALE; RETROSPECTIVE STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; CAT DISEASES; CATS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; RETROSPECTIVE STUDIES; THIAZINES; THIAZOLES;

FELIDAE;

EID: 70450043620     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00194.x     Document Type: Article

References (29)

1. Lana SE, Rutteman GR, Withrow SJ, Withrow SJ, MacEwen EG. Tumors of the mammary gland. Small Animal Clinical Oncology 2007, 619-636. In:, 4th edn., eds.,, Philadelphia, Saunders
2. Hayes AA, Mooney S. Feline mammary tumors. The Veterinary Clinics of North America Small Animal Practice 1985, 15:513-520.
3. Novosad CA, Bergman PJ, O'Brien MG, McKnight JA, Charney SC, Selting KA, Graham JC, Correa SS, Rosenberg MP, Gieger TL. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. Journal of the American Animal Hospital Association 2006, 42:110-120.
4. Ito T, Kadosawa T, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N. Prognosis of malignant mammary tumor in 53 cats. The Journal of Veterinary Medical Science 1996, 58:723-726.
5. McNeill CJ, Sorenmo KU, Shofer FS, Gibeon L, Durham AC, Barber LG, Baez JL, Overley B. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. Journal of Veterinary Internal Medicine 2009, 23:123-129.
6. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramell M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. Journal of Comparative Pathology 1998, 119:263-275.
7. MacEwen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S. Prognostic factors for feline mammary tumours. Journal of the American Veterinary Medical Association 1984, 185:201-204.
8. Viste JR, Myers SL, Singh B, Simko E. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. The Canadian Veterinary Journal 2002, 43:33-37.
9. Overley B, Shofer FS, Goldschmidt MH, Sherer D, Sorenmo KU. Association between ovarihysterectomy and feline mammary carcinoma. Journal of Veterinary Internal Medicine 2005, 19:560-563.
10. Hayes A. Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs - can we combine all three?. Veterinary and Comparative Oncology 2007, 5:1-75.
11. Beam SL, Rassnick KM, Moore AS, McDonough SP. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Veterinary Pathology 2003, 40:496-500.
12. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 2003, 40:33-44.
13. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Research 2003, 63:906-911.
14. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research 2002, 62:632-635.
15. Davies G, Salter J, Hils M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clinical Cancer Research 2003, 9:2651-2656.
16. Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Research 2004, 24:2349-2351.
17. Millanta F, Citi S, Della Santa D, Porciani M, Poli A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Research and Treatment 2006, 98:115-120.
18. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA, Mukherjee P. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Research 2006, 8:R69.
19. De Maria R, Maggiora P, Biolatti B, Prat M, Comoglio PM, Castagnaro M, Di Renzo MF. Feline STK gene expression in mammary carcinomas. Oncogene 2002, 21:1785-1790.
20. Millanta F, Calandrela M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Journal of Veterinary Pathology 2005, 42:30-34.
21. Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M. Feline mammary tumours in comparative oncology. The Journal of Dairy Research 2005, 72:98-106.
22. Heller DA, Fan TM, de Lorimier LP, Charney SC, Barger AM, Tannehill-Gregg SH, Rosol TJ, Wallig MA. In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells. Journal of Veterinary Internal Medicine 2007, 21:1048-1055.
23. Lascelles BD, Court MH, Hardie EM, Robertson SA. Nonesteroidal anti-inflammatory drugs in cats: a review. Journal of Veterinary Anaesthesia and Analgesia 2007, 34:228-250.
24. Lascelles BD, Henderson AJ, Hackett IJ. Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. The Journal of Small Animal Practice 2001, 42:587-593.
25. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v10. Veterinary and Comparative Oncology 2004, 2:195-213.
26. IRIS 2006 Staging of CKD. http://www.iris-kidney.com/guidelines/en/staging_ckd.shtml, IRIS (International Renal Interest Society), 2006., [accesed 5 May 2008]
27. Lees P, Giraudel J, Landoni MF, Toutain PL. PK-PD integration and PK-PD modelling of non-steroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:479-490.
28. O'Keefe DA, Sisson DD, Gelberg HB, Schaeffer DJ, Krawiec DR. Systemic toxicity associated with doxorubicin administration in cats. Journal of Veterinary Internal Medicine 1993, 7:309-317.
29. Mauldin GN, Matus RE, Patnaik AK, Bond BR, Mooney SC. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. Journal of Veterinary Internal Medicine 1988, 23:60-65.